Tian Y, et al. – In this study, researchers determined whether cell-division cycle-associated 5 (CDCA5), a cell cycle regulatory protein, has any prognostic value in hepatocellular carcinoma (HCC). For this purpose, the investigators retrospectively assessed 178 patients with HCC treated with curative liver resection between September 2009 and September 2012 at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients were divided into high or low expression groups, based on their CDCA5 expression levels. Both groups were compared with respect to patient demographics, comorbidities, clinicopathologic data, such as tumor microvascular invasion status and size, and long-term outcomes. Using in vitro and in vivo assays, they analyzed the impact of CDCA5 on the proliferation of liver cancer cells. Overall, they found that CDCA5 expression was related to poor prognosis in patients with HCC.